MicroRNAs could be key to treating heart failure, according to a study out of Boston Children’s Hospital and Zhejiang University School of Medicine in China.

The University of Southern California will lose its cardiology fellowship accreditation after more than a year of unrest within the medical school, the Los Angeles Times reported April 25.

A national effort to recall carcinogen-tainted batches of the popular blood pressure drug losartan has once again expanded, growing to include one lot of the medication distributed by Legacy Pharmaceutical Packaging, LLC.

The Radiological Society of North America (RSNA) on April 25 launched the first issue of its newest online journal, Radiology: Cardiothoracic Imaging.

Antibiotic use—particularly regimens that last for two months or more—was linked to an increased risk of CVD in a recent study of nearly 36,500 older women.

Five milligrams of rivaroxaban per day added to a patient’s standard therapy for heart failure (HF) and coronary artery disease (CAD) could reduce that patient’s risk of future thromboembolic events, researchers reported in JAMA Cardiology April 24.

Guerbet, a medical imaging company out of Villepinte, France, this week announced it received CE mark approval for its SeQure and DraKon devices, two microcatheters that facilitate the intra-arterial delivery of therapies and embolic materials to peripheral vessels.

Pennsylvania-based health company Orchestra BioMed has obtained FDA breakthrough device designation for its Virtue sirolimus-eluting balloon (SEB), according to a statement issued April 24.

Around a quarter of heart patients who undergo percutaneous coronary intervention (PCI) are readmitted to the hospital for unplanned reasons within six months of their procedure, researchers report in JACC: Cardiovascular Interventions.

The global wearable medical devices market is expected to surpass $29 billion by 2026, according to a report from Transparency Market Research (TMR), expanding at a projected compound annual growth rate (CAGR) of more than 17% over the next seven years.

The FDA’s Circulatory System Devices Panel of the Medical Devices Advisory Committee will meet in mid-June to discuss recent controversies and safety practices surrounding paclitaxel-coated and -eluting medical devices, according to a notice posted April 22.

Boston Scientific’s LOTUS Edge Aortic Valve System was cleared by the FDA April 23 for use in high-risk surgical candidates with severe aortic stenosis.